Alzheimer’s disease Diagnostics and Therapeutics Market to Surpass US$ 9,503.1 Million by 2030, Says Coherent Market Insights (CMI)

Burlingame, March 06, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global Alzheimer’s disease diagnostics and therapeutics market is estimated to be valued at US$ 6,231.1 million in 2022 and is expected to exhibit a CAGR of 5.4 % during the forecast period (2022-2030).

Key Trends and Analysis of the Global Alzheimer’s Disease Diagnostics and Therapeutics Market:

Increase in number of clinical trials conducted on AD is expected to drive the market growth. According to an article published in the National Center for Biotechnology Information (NCBI), in May 2022, as of January 25, 2022 (the study's index date), 172 clinical trials were being conducted globally with 143 different AD agents as per clinicaltrials.gov. The pipeline contained 31 drugs in 47 Phase 3 studies, 82 compounds in 94 Phase 2 trials, and 30 agents in 31 Phase 1 trials. Drugs for the treatment of neuropsychiatric symptoms make up 6.9% of the agents in trials, while disease-modifying therapies make up 83.2% of the total. Symptomatic cognitive boosting treatments make up 9.8% of the agents in trials. Drugs in studies include a wide range of therapeutic targets, including almost all Common Alzheimer's Disease Research Ontology (CADRO) categories. About 37% of the candidate compounds in development are modified versions of medications already approved for use in other conditions. In order to meet recruitment standards, a total of 50,575 participants are required, for all currently active clinical trials.

Increasing demand for safe and effective Alzheimer’s disease therapeutics is expected to offer significant growth opportunities for players in the global Alzheimer’s disease diagnostics and therapeutics market

For instance, in June 2021, Eli Lilly and Company announced that the U.S. Food and Drug Administration (USFDA) had granted breakthrough therapy designation for donanemab, its investigational antibody therapy for the treatment of Alzheimer’s disease. The company also intends to submit a biologics license application under accelerated approval pathway based on data from the phase 2 study.

Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/5181

Alzheimer’s disease Diagnostics and Therapeutics Market Report Coverage

Key Market Takeaways:

The global Alzheimer’s disease diagnostics and therapeutics market is expected to exhibit a CAGR of 5.4% during the forecast period due to increasing awareness among people about novel diagnostics and therapeutics for AD. For instance, in March 2021, the Alzheimer’s Association launched ‘More Time’, a campaign to increase awareness and demonstrate the strong desire by those living with or facing Alzheimer's for a disease-modifying treatment in U. S. The campaign included full-page print advertising, digital advertising, social media, and email marketing, as well as online town hall meeting. People affirmed their support over 1.1 million times, and the campaign received more than 90 million media impressions.

Among product, diagnostics segment is expected to hold a dominant position over the forecast period, owing to increasing collaborations by the key players. For instance, on March 1, 2022, Quanterix, a life sciences company and Eli Lilly and Company, a pharmaceutical company announced that they have signed a collaboration agreement for the diagnosis, monitoring, and treatment of Alzheimer’s disease. As part of the partnership, Quanterix will receive a non-exclusive, global license to Lilly's proprietary P-tau217 antibody technology for potential future use in in vitro diagnostic applications as well as products and services for research use only.

Among region, North America is expected to hold the dominating position in the global Alzheimer’s disease diagnostics and therapeutics market, owing to increasing approvals for the advanced techniques for Alzheimer’s disease diagnosis in the region by the regulatory bodies. For instance, on May 4, 2022, Fujirebio, a subsidiary of H.U. Group Holdings, Inc., which is a producer and supplier of in vitro diagnostics products, announced that it had received approval of its product Lumipulse G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test for FDA marketing authorization for the assessment of Alzheimer’s disease in the U.S. by the U.S. Food and Drug Administration (FDA).

Competitive Landscape:

Key players operating in the global Alzheimer’s disease diagnostics and therapeutics market include Luye Pharma Group, Vigil Neuroscience, Inc., Grifols, S.A., AbbVie Inc., Zydus Lifesciences Ltd., Merck KGaA, F. Hoffmann-La Roche Ltd., Novartis AG, Johnson & Johnson, Eli Lilly and Company, Biogen Inc., Siemens Healthcare GmbH, Merz Pharma, Eisai Co. Ltd., Lupin Limited, Teva Pharmaceutical Industries Ltd., Apotex Inc., Corium, Inc., Supernus Pharmaceuticals, Inc.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/5181

Market Segmentation:

• Global Alzheimer’s Disease Diagnostics And Therapeutics Market, By Product:
  • Therapeutics
    • Cholinesterase Inhibitors
    • NMDA Receptor Antagonists
    • Others 
  • Diagnostics   
    • Brain Imaging
    • CSF Test for Alzheimer’s Disease
• Global Alzheimer’s Disease Diagnostics And Therapeutics Market, By Region:
  • North America
    • By Country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Region/Country
      • South Africa
      • Central Africa
      • North Africa
        

Related Market Intelligence Reports:

Digestive Drugs Market, By Type (Branded and Generic), By Drug Class (5-aminosalicylates, GI stimulants, Laxatives, Antacids, H2 Antagonists, Antidiarrheals, Others), By Route of Administration (Oral, Intravenous, Others), By Application (Gastroesophageal Reflux Disease (GERD), Irritable Bowel Syndrome, Ulcerative Colitis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030

Peptide Therapeutics Market, By Product Type (Branded Peptide and Generic Peptide), By Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, and Others), By Route of Administration (Oral Administration, Parenteral Administration, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 – 2030

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Follow Us: LinkedIn | Twitter